<DOC>
	<DOCNO>NCT01815333</DOCNO>
	<brief_summary>The goal clinical research study learn drug Feraheme ® ( ferumoxytole ) help researcher clearly `` see '' cancerous lymph node MRI scan . Researchers also want learn ferumoxytole may use liver image . Ferumoxytole design deliver iron treat iron-deficiency anemia ( low red blood cell count ) patient chronic kidney disease . In study , use MRI contrast . Contrasts use doctor order see MRI image clearly .</brief_summary>
	<brief_title>Clinical Technical Feasibility Ultrasuperparamagnetic Nanoparticle Iron Oxide ( USPIO ) -Enhanced Magnetic Resonance Lymph Node Imaging</brief_title>
	<detailed_description>Study Participation : If find eligible , follow MRI scan , pas long , narrow tube scanner , open end . You total 3 MRI scan . You MRI scan receive ferumoxytole need . This standard-of-care MRI scan . You receive ferumoxytole vein . If schedule MRI scan abdomen , visible lymph node abdomen , stay MRI scanner extra 30 minute liver image right receive dose ferumoxytole . This part investigational scan ( Visit 1 -- Day 1 ) You return MRI scan 2 day later ( Visit 2 -- Day 2 ) follow day ( Visit 3 -- Day 3 ) scan lymph node . These investigational scan . The timing second third scan may change base study doctor 's decision . Length Study : Your participation study third MRI scan . Additional Information : The image collect part study include part medical record . If image and/or information study use publication , identifiable information remove . The data store 5 year study data publish . This investigational study . Ferumoxytole FDA approve commercially available treatment iron-deficiency anemia patient chronic kidney disease . Its use help researcher `` see '' cancerous lymph node MRI scan consider investigational . Up 18 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>1 . Enrolled MDACC , Written consent 2 . Measurable nodes recent cross sectional imaging ( CT , MRI . US ) suspicious lymph node metastasis 3 . Requiring tissue diagnosis ( FNA , core biopsy , surgical biopsy , surgical resection ) , clinical followup least 6 month . 4 . Any primary disease sit abdomen pelvis allow 1 . Primary secondary iron overload 2 . Lactation pregnant woman child bear potential exclude 3 . Contraindications MRI 4 . Contraindication allergy Feraheme® ( base insert ) 5 . Clinically document risk primary secondary iron overloading ( e.g . History thalassemia , sickle cell anemia , hereditary hemochromatosis , multiple transfusion reason ) , anemia cause iron deficiency 6 . Age 18</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Cancer Lymph Node</keyword>
	<keyword>Magnetic resonance imaging</keyword>
	<keyword>MRI</keyword>
	<keyword>Ultrasuperparamagnetic nanoparticle iron oxide</keyword>
	<keyword>USPIO</keyword>
	<keyword>Feraheme</keyword>
	<keyword>Ferumoxytole</keyword>
</DOC>